Fact CheckerSign in

NCT02516033Completed

Hybrid Atrial Fibrillation Ablation Registry

Identification of a Risk Profile Associated With Failure of the Hybrid Ablation of Atrial Fibrillation.

Source: ClinicalTrials.gov · Last updated 3 Jun 2026

Brief summary (registry, in English)

Recently a combined approach of surgeon ablation in combination with endocardial ablation (hybrid ablation) has been introduced. This therapy has shown excellent results in patients with previous failed endocardial ablation for paroxysmal atrial fibrillation as well in patients with persistent atrial fibrillation. The investigators hypothesize that the severity of atrial remodeling in patients with atrial fibrillation can be measured by clinical factors, echocardiographic parameters, circulating biomarkers and genetic background, and that these factors can be used to identify a risk profile to predict failure of the hybrid ablation therapy in patients with atrial fibrillation. Aim of this study is to determine a risk profile based on clinical correlates, circulating biomarkers, and genetic background associated with failure of the hybrid ablation procedure, in a prospective single center registry setting. The investigators evaluate all consecutive patients who have agreed to undergo the hybrid ablation procedure because of atrial fibrillation. The investigators aim for a total of 250 participants. Extra study related procedures include blood sampling for biomarkers and genetic analysis, prolonged Holter monitoring for documentation of recurrences of atrial fibrillation/atrial flutter/atrial tachycardias, and a quality of life questionnaire. Total follow-up will be five years. Main study endpoint is failure of the hybrid ablation procedure in patients with atrial fibrillation, i.e. any (a)symptomatic atrial fibrillation/atrial flutter/atrial tachycardia \>30sec without anti-arrhythmic drugs at one year of follow-up by ECG recording and 3-day Holter monitoring.

Status (registry)
Completed
Study type
Observational
Enrollment
250 (actual)
First submitted
3 Aug 2015
Start date
Jan 2015
Primary completion date
May 2026
Lead sponsor
University Medical Center Groningen
NCT number
NCT02516033

What you commit to

  • Study type: Observational
  • Participants enrolled: 250
  • From Jan 2015 to the primary completion date, May 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • None.

Who the study is looking for

  • Patients who have agreed to undergo the hybrid ablation procedure because of atrial fibrillation.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.